NASDAQ · ZVRA
Zevra Therapeutics, Inc.
$10.26-$0.10 (-0.99%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.8% below the high.
Loading market information…
NASDAQ · BSGM · USD
Stock price, earnings
Quote as of Sep 11, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BioSig Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioSig Technologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioSig Technologies, Inc., along with its subsidiaries, operates as a medical technology enterprise. Its core innovation is the PURE EP (precise uninterrupted real-time evaluation of electrograms electrophysiology) system. This proprietary signal processing platform, merging specialized hardware and software, tackles well-known difficulties in electrophysiological signal acquisition, empowering electrophysiologists to instantaneously view and analyze vital cardiac signals. The system further enhances the collection of intracardiac signals and diagnostic data crucial for atrial fibrillation procedures. Moreover, it is specifically engineered to overcome persistent obstacles that traditionally slow down and complicate cardiac catheter ablation. BioSig also holds a research agreement with the University of Minnesota, targeting the development of new treatments for sympathetic nervous system disorders. Additionally, it has a strategic partnership with the Mayo Foundation for Medical Education and Research, focused on creating an advanced AI and machine learning software solution tailored for its PURE EP platforms. Established in 2009, BioSig Technologies, Inc. is headquartered in Westport, Connecticut.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $1.00K-99.0% vs estimate |
| Q2 2023 | Aug 14, 2023 | -$1.60-1,500.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.26-$0.10 (-0.99%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.8% below the high.
$5.84$0.00 (0.0%)
Nevro Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.09% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$4.07+$0.01 (+0.12%)
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
$3.08-$0.42 (-11.89%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.43% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
